Skip to main content
. 2017 Sep 20;12(9):e0184841. doi: 10.1371/journal.pone.0184841

Fig 5. The effect of tumoral IL-17 positive cells upon patient outcome.

Fig 5

A: Patients who had NMIBCs with concomitant CIS were divided into IL-17hi (n = 14) and IL-17low (n = 52) groups based on the upper quartile of IL-17 positive cell counts in this group of patients (374.5 IL-17 positive cells per 10 high power fields). B: Patients who received BCG immunotherapy were divided into IL-17hi (n = 6) and IL-17lo (n = 36) groups, using the same criteria as before. Significance was calculated using the Log-rank (Mantel-Cox) test. Dotted line indicates 95% CI.